Briefs: Zydus and CuraTeQ Biologics
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Topiramate is indicated as a treatment of epilepsy and migraine
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The product will be launched in Q1FY26
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Subscribe To Our Newsletter & Stay Updated